Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
Represented Northwestern University, and an inventor affiliated with Northwestern University, in a series of royalty monetizations (structured both as sales and as financings through special purpose vehicles), including Northwestern’s 2007 sale of a portion of its worldwide royalty interest in Lyrica for $700 million, the largest monetization of a royalty stream for a single pharmaceutical product.
Represented The Kennedy Trust for Rheumatology Research (a UK charitable trust which currently funds a major research institute at Oxford University) in the structured sale of a portion of its worldwide royalty interests in Remicade and Simponi.
Represented University of Pennsylvania in the structured sale of a portion of its worldwide royalty interests in Juxtapid.
Represented Emory University in a ground-breaking sale of its royalty interests in Emtriva for $540 million, the first royalty monetization conducted by auction and IDD’s 2005 Healthcare Deal of the Year.
Represented Duke University in the sale of a portion of its worldwide royalty interests in Myozyme and Lumizyme.
August 5, 2016
NEW YORK—Covington advised Dana-Farber Cancer Institute in its monetization of a portion of its interest in royalties related to its Programmed Death Ligand-1 (PD-L1) intellectual property. PD-L1 inhibitors are immuno-oncology drugs used for the treatment of various types of metastatic cancer.
CPPIB Credit Europe S.à r.l., a wholly owned subsidiary of Canada ...
July 15, 2016
NEW YORK—Covington advised Medical Research Council Technology, a UK-based independent life science medical research charity, in its sale of a portion of the royalty stream associated with its cancer drug Keytruda® for $150 million (£115.6 million).
Keytruda® (pembrolizumab), is a new generation treatment which stimulates the body’s immune system to fight ...
NEW YORK, NY, December 18, 2007 — Covington & Burling LLP advised Northwestern University in the sale of a portion of its worldwide royalty interest in Lyrica® to Royalty Pharma for $700 million in cash. The transaction is the largest sale ever of a royalty stream for a pharmaceutical product. John Gourary, co-head of Covington’s finance practice, together with ...